THALIDOMIDE APPROVAL RECOMMENDATION WOULD OVERRULE FDA PRIMARY REVIEWERS, DIVISION DIRECTOR; REVIEW WOULD BE SYMBOL OF NEW FDA THEMES OF PATIENT ACCESS

The FDA advisory committee recommendation to approve Celgene's thalidomide for use in the treatment of systemic erythema nodosum leprosum contrasts with the non-approval recommendations of the primary reviewers and division director.